» Articles » PMID: 37925183

Methods for the Study of Ribonuclease Targeting Chimeras (RiboTACs)

Overview
Journal Methods Enzymol
Specialty Biochemistry
Date 2023 Nov 4
PMID 37925183
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, a class of heterobifunctional small molecules called ribonuclease targeting chimeras (RiboTACs) have been developed that selectively induce degradation of RNAs in cells. These molecules function by recruiting latent ribonuclease (RNase L), an endoribonuclease involved in the innate immune response, to targeted RNA structures. The RiboTACs must activate RNase L in proximity to the RNA, resulting in cleavage of the RNA and downstream degradation. To develop and validate a new RiboTAC, several steps must be taken. First, small molecule activators that bind to RNase L must be identified. Next, since RNase L is only catalytically active upon ligand-induced homodimerization, the capability of identified small molecules to activate RNase L must be assessed. RNase L-activating small molecules should then be coupled to validated RNA-binding small molecules to construct the active RiboTAC. This RiboTAC can finally be assessed in cells for RNase L-dependent degradation of target RNAs. This chapter will provide several methods that are helpful to develop and assess RiboTACs throughout this process, including recombinant RNase L expression, methods to assess RNase L engagement in vitro such as saturation transfer difference nuclear magnetic resonance (STD NMR), an in vitro assay to assess activation of RNase L, and cellular methods to demonstrate RNase L-dependent cleavage.

References
1.
Gupta A, Rath P . Expression, purification and characterization of the interferon-inducible, antiviral and tumour-suppressor protein, human RNase L. J Biosci. 2012; 37(1):103-13. DOI: 10.1007/s12038-011-9180-4. View

2.
Costales M, Aikawa H, Li Y, Childs-Disney J, Abegg D, Hoch D . Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proc Natl Acad Sci U S A. 2020; 117(5):2406-2411. PMC: 7007575. DOI: 10.1073/pnas.1914286117. View

3.
Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

4.
Borgelt L, Haacke N, Lampe P, Qiu X, Gasper R, Schiller D . Small-molecule screening of ribonuclease L binders for RNA degradation. Biomed Pharmacother. 2022; 154:113589. DOI: 10.1016/j.biopha.2022.113589. View

5.
Thakur C, Jha B, Dong B, Das Gupta J, Silverman K, Mao H . Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc Natl Acad Sci U S A. 2007; 104(23):9585-90. PMC: 1877983. DOI: 10.1073/pnas.0700590104. View